A cancer biotech backed by Atlas Venture and F-Prime Capital has drawn the attention of some of the biggest names in oncology drugs and tripled its cash in a new financing round.

Xilio Therapeutics has raised $100.5 million in a Series B round, a threefold increase over the $30 million it raised in 2018. The firm also debuted a name change from Akrevia Therapeutics. Its new moniker is derived from the Latin term “ex nihilo,” meaning creation or big-bang.  

Takeda Pharmaceuticals Co. Ltd.’s…

Boston Biz Journal https://www.bizjournals.com/boston/news/2020/03/02/takeda-merck-invest-in-waltham-cancer-startups.html?ana=RSS&s=article_search